1---2name: quality-agreement3description: Drafts Quality Agreements for pharmaceutical contract manufacturing. Assigns quality roles between product owners and CMOs under FDA cGMP (21 CFR 210/211), ICH Q7, and related guidance. Use when a user needs a quality agreement, CMO quality terms, or cGMP compliance agreement for contract manufacturing.4license: Apache-2.05---67# Quality Agreement for Contract Manufacturing89Drafts an enforceable Quality Agreement defining quality roles, responsibilities, and cGMP compliance obligations between a product owner and a contract manufacturing organization (CMO).1011## Prerequisites12131. **Manufacturing/supply agreement** — commercial terms, product scope, facility details142. **Regulatory identifiers** — FDA Establishment IDs, DUNS, DEA registrations (if controlled), ISO certs153. **Product details** — dosage form, API/finished product, classification (Rx, OTC, biologic)164. **Existing quality documents** — prior quality agreements, SOPs, inspection history (483s, warning letters)175. **Specifications** — approved specs, analytical methods, stability protocols1819Search user-uploaded documents for existing agreements, specs, and regulatory correspondence before drafting.2021## Output Structure2223| Section | Key Contents |24|---------|-------------|25| Parties & Scope | Legal names, regulatory IDs, product scope, exclusions, quality-over-commercial supremacy clause |26| Definitions | Regulatory terms, party-specific roles |27| Quality Unit Authority | Responsibility matrix (see below), independence provisions, escalation paths |28| Manufacturing & Documentation | Batch records, retention per 21 CFR 211.180, Part 11 compliance |29| Change Control | Categories, approval workflows, review timelines (see below) |30| Audit & Inspection | Routine/for-cause/unannounced rights, 483 response coordination |31| Quality Events & CAPA | Deviation reporting, investigation, CAPA approval, recall authority |32| Specifications & Release | Method validation (ICH Q2), OOS investigations, stability programs |33| Personnel & Training | Qualifications, training programs, key personnel change notice |34| Term & Termination | Duration, termination rights, transition obligations, survival clauses |35| Appendices | Change control forms, deviation templates, quality metrics, contacts |3637### Quality Unit Responsibility Matrix3839| Function | Product Owner | CMO |40|----------|:---:|:---:|41| Final batch disposition | ● | |42| In-process controls execution | | ● |43| Specification approval | ● | |44| Deviation investigation | | ● |45| Deviation report approval | ● | |46| Regulatory submissions | ● | |47| Environmental monitoring | | ● |48| Equipment qualification | | ● |49| Change control approval (major) | ● | |50| Complaint handling (mfg-related) | | ● |51| Recall decision authority | ● | |5253### Notification Timelines5455| Event | Deadline |56|-------|----------|57| Critical quality event (safety/regulatory) | 24 hours |58| Significant quality event | 72 hours |59| Routine quality event | 5 business days |60| Unannounced regulatory inspection | 4 hours |61| Announced regulatory inspection | 24 hours |62| Key personnel change | 30 days advance |6364### Change Control Framework6566| Category | Examples | Approval | Review Period |67|----------|----------|----------|---------------|68| Minor | Admin SOP updates, like-for-like equipment | CMO QU (notify owner) | 15 business days |69| Major | Critical process params, alt. suppliers, method revisions | Product owner QU written approval | 30 business days |70| Emergency | Immediate safety/compliance | CMO implements → retrospective owner approval | Immediate |7172Change proposals must include: description, scientific justification, risk assessment (FMEA/ICH Q9), validation protocols if applicable, regulatory impact analysis, implementation timeline.7374### Audit Rights7576- **Pre-approval** — before manufacturing initiation77- **Routine** — ≤24-month intervals, 30 days advance notice78- **For-cause** — triggered by quality events or regulatory concerns79- **Unannounced** — preserved right for serious quality/regulatory concerns80- **Scope** — unrestricted access to batch records, validation reports, deviations, training records, personnel interviews, facility inspection81- **Post-audit** — report within 30 days; CMO CAPA response within 15 business days8283### Batch Records & Documentation8485- Contemporaneous recording (indelible ink or validated electronic systems)86- Complete material genealogy and traceability87- CMO initial review: 5–10 business days post-batch completion88- Product owner QU review: 10–15 additional business days before disposition89- Retention: ≥1 year past expiry or 3 years post-distribution (whichever longer) per 21 CFR 211.18090- Part 11 compliance: system validation, audit trails, data integrity controls9192### Termination & Transition9394- **Non-renewal notice**: ≥180 days before term expiry95- **Material breach cure**: 60 days from written notice96- **Convenience termination**: 180–360 days advance notice97- **Post-termination**: CMO supports product through shelf life (stability, reserve samples, complaints, inspections)98- **Document transfer**: Complete batch records and quality documentation within 90 days99- **Survival**: Confidentiality (indefinite), record retention (regulatory periods), regulatory support (while product in distribution)100101## Guidelines102103- Use mandatory language ("shall," "must") — never aspirational ("should," "will")104- Include explicit quality-over-commercial supremacy clause; quality decisions independent from commercial considerations105- Align with FDA 2016 Guidance: Contract Manufacturing Arrangements for Drugs: Quality Agreements [VERIFY]106- Address data integrity per FDA 2018 Data Integrity and Compliance with Drug CGMP guidance [VERIFY]107- For international markets, incorporate ICH Q7, EU GMP Annex 11, WHO guidelines as applicable108- Include cybersecurity provisions for manufacturing systems and confidential regulatory data109- Quality agreement governs all quality matters; ensure no conflict with underlying supply agreement110- If user provides 483s or warning letters, incorporate preventive measures addressing cited deficiencies
ThomasMoreAI